A double-blind, placebo-controlled intervention trial of 3 and 10 mg sublingual melatonin for post-concussion syndrome in youths (PLAYGAME): study protocol for a randomized controlled trial
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: By the age of sixteen, one in five children will sustain a mild traumatic brain injury also known as concussion. Our research found that one in seven school children with mild traumatic brain injury suffer post-concussion syndrome symptoms for three months or longer. Post-concussion syndrome is associated with significant disability in the child and his/her family and yet there are no evidence-based medical treatments available. Melatonin has several potential mechanisms of action that could be useful following mild traumatic brain injury, including neuroprotective effects. The aim of this study is to determine if treatment with melatonin improves post-concussion syndrome in youths following mild traumatic brain injury. Our hypothesis is that treatment of post-concussion syndrome following mild traumatic brain injury with 3 or 10 mg of sublingual melatonin for 28 days will result in a decrease in post-concussion syndrome symptoms compared with placebo. METHODS/DESIGN: Ninety-nine youths with mild traumatic brain injury, aged between 13 and 18 years, who are symptomatic at 30 days post-injury will be recruited. This study will be conducted as a randomized, double blind, placebo-controlled superiority trial of melatonin. Three parallel treatment groups will be examined with a 1:1:1 allocation: sublingual melatonin 3 mg, sublingual melatonin 10 mg, and sublingual placebo. Participants will receive treatment for 28 days. The primary outcome is a change on the Post-Concussion Symptom Inventory (Parent and Youth). The secondary outcomes will include neurobehavioral function, health-related quality of life and sleep. Neurophysiological and structural markers of change, using magnetic resonance imaging techniques and transcranial magnetic stimulation, will also be investigated. DISCUSSION: Melatonin is a safe and well-tolerated agent that has many biological properties that may be useful following a traumatic brain injury. This study will determine whether it is a useful treatment for children with post-concussion syndrome. Recruitment commenced on 4 December 2014. TRIAL REGISTRATION: This trial was registered on 6 June 2013 at ClinicalTrials.gov. REGISTRATION NUMBER: NCT01874847.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderate and severe traumatic brain injury in adults
Maas, A. I., Stocchetti, N., & Bullock, R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70164-9 · Cited by 2,123
The molecular pathophysiology of concussive brain injury
Barkhoudarian, G., Hovda, D. A., & Giza, C. C. (2011) · Clinics in Sports Medicine · doi:10.1016/j.csm.2010.09.001 · Cited by 492 · cited 3×
“Most animal studies demonstrate recovery from mTBI within 7 to 15 days [22,29,30], similar to the clinical experience of the majority of humans [6,10,12].”
Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L., Vohra, S., Klassen, T. P., & Baker, G. (2006) · BMJ · doi:10.1136/bmj.38731.532766.f6 · Cited by 454
The efficacy and safety of exogenous melatonin for primary sleep disorders a meta-analysis
Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L., Baker, G., Klassen, T. P., & Vohra, S. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0243.x · Cited by 399 · cited 2×
“For all adverse events, there was no significant difference between melatonin and the placebo [144].”
Andrews-Zwilling, Y., Bien-Ly, N., Xu, Q., Li, G., Bernardo, A., Yoon, S. Y., Zwilling, D., Yan, T. X., Chen, L., & Huang, Y. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4040-10.2010 · Cited by 326
Gagnon, I., Swaine, B., Friedman, D., & Forget, R. (2005) · Journal of Head Trauma Rehabilitation · doi:10.1097/00001199-200509000-00005 · Cited by 64 · cited 2×
“It is associated with significant disability in the child and his/ her family [5,12-17].”
Interventions provided in the acute phase for mild traumatic brain injury: a systematic review
Gravel, J., D’Angelo, A., Carrière, B., Crevier, L., Beauchamp, M. H., Chauny, J.-M., Wassef, M., & Chaillet, N. (2013) · Systematic Reviews · doi:10.1186/2046-4053-2-63 · Cited by 53 · cited 1×
“There are few evidence-based treatments for PCS that persists for one month or more [37,40,43,44,51-53], providing the clinician with little guidance for the management of significantly debilitated patients [54].”
Brooks, B. L., & Sherman, E. M. S. (2012) · Journal of Child Neurology · doi:10.1177/0883073811430863 · Cited by 41
Self-citation
Cited by
Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research
Maas, A. I. R., Menon, D. K., Adelson, P. D., Andelic, N., Bell, M. J., Belli, A., Bragge, P., Brazinova, A., Büki, A., Chesnut, R. M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30371-x · Cited by 2,609
Self-citationLofitou, K., Kouki, E. P., Gavriel, C., Achilleos, H., Themistokleous, V., Bargiotas, P., Haarbauer‐Krupa, J., Paraskevopoulos, E., & Constantinidou, F. (2026) · Brain and Behavior · doi:10.1002/brb3.71556
Metadata
- Authors
- Barlow, K. M., Brooks, B. L., MacMaster, F. P., Kirton, A., Seeger, T., Esser, M., Crawford, S., Nettel-Aguirre, A., Zemek, R., Angelo, M., Kirk, V., Emery, C. A., Johnson, D., Hill, M. D., Buchhalter, J., Turley, B., Richer, L., Platt, R., Hutchison, J., & Dewey, D.
- Venue
- Trials
- Published
- 2014-07-07
- Volume
- 15
- Issue
- 1
- Pages
- 271-271
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2131859465
- Cited by
- 49
- References
- 8
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A double-blind, placebo-controlled intervention trial of 3 and 10 mg sublingual melatonin for post-concussion syndrome in youths (PLAYGAME): study protocol for a randomized controlled trial. https://app.cochat.ai/papers/10.1186/1745-6215-15-271
- The paper
- Barlow, K. M., Brooks, B. L., MacMaster, F. P., Kirton, A., Seeger, T., Esser, M., Crawford, S., Nettel-Aguirre, A., Zemek, R., Angelo, M., Kirk, V., Emery, C. A., Johnson, D., Hill, M. D., Buchhalter, J., Turley, B., Richer, L., Platt, R., Hutchison, J., & Dewey, D. (2014). A double-blind, placebo-controlled intervention trial of 3 and 10 mg sublingual melatonin for post-concussion syndrome in youths (PLAYGAME): study protocol for a randomized controlled trial. Trials. https://doi.org/10.1186/1745-6215-15-271
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.